Chris Recknor

4.0k total citations · 1 hit paper
37 papers, 2.8k citations indexed

About

Chris Recknor is a scholar working on Orthopedics and Sports Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Chris Recknor has authored 37 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Orthopedics and Sports Medicine, 22 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Chris Recknor's work include Bone health and osteoporosis research (31 papers), Bone health and treatments (22 papers) and Bone Metabolism and Diseases (14 papers). Chris Recknor is often cited by papers focused on Bone health and osteoporosis research (31 papers), Bone health and treatments (22 papers) and Bone Metabolism and Diseases (14 papers). Chris Recknor collaborates with scholars based in United States, Canada and Belgium. Chris Recknor's co-authors include Steven Boonen, Peter Mesenbrink, Erik Fink Eriksen, Jonathan D. Adachi, Kenneth W. Lyles, Lars Nordsletten, Jay Magaziner, Cathleen Colón‐Emeric, Lars Hyldstrup and C. Mautalén and has published in prestigious journals such as New England Journal of Medicine, Journal of Bone and Mineral Research and Annals of the Rheumatic Diseases.

In The Last Decade

Chris Recknor

36 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

2007 1.4k citations Kenneth W. Lyles, Cathleen Colón‐Emeric et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Recknor United States	19	2.4k	1.7k	917	846	223	37	2.8k
Nicola Peel United Kingdom	30	1.6k 0.7×	911 0.5×	698 0.8×	604 0.7×	107 0.5×	69	2.5k
Jose Adolfo Rodriguez-Portales Chile	9	2.8k 1.2×	2.3k 1.3×	589 0.6×	1.0k 1.2×	204 0.9×	11	3.4k
Susan B. Broy United States	15	1.2k 0.5×	463 0.3×	578 0.6×	290 0.3×	119 0.5×	24	1.5k
Kyoungah See United States	16	664 0.3×	501 0.3×	305 0.3×	380 0.4×	213 1.0×	36	1.4k
T. Storm Denmark	19	995 0.4×	691 0.4×	207 0.2×	462 0.5×	86 0.4×	47	1.7k
Clarita V. Odvina United States	17	1.4k 0.6×	1.1k 0.7×	423 0.5×	357 0.4×	268 1.2×	24	2.1k
Marc C. Hochberg United States	8	508 0.2×	286 0.2×	573 0.6×	291 0.3×	117 0.5×	9	2.1k
Frances Milat Australia	21	457 0.2×	317 0.2×	204 0.2×	340 0.4×	75 0.3×	74	1.3k
P Meunier France	15	671 0.3×	437 0.3×	245 0.3×	192 0.2×	78 0.3×	54	1.2k

Countries citing papers authored by Chris Recknor

Since Specialization

Citations

This map shows the geographic impact of Chris Recknor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Recknor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Recknor more than expected).

Fields of papers citing papers by Chris Recknor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Recknor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Recknor. The network helps show where Chris Recknor may publish in the future.

Co-authorship network of co-authors of Chris Recknor

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Recknor. A scholar is included among the top collaborators of Chris Recknor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Recknor. Chris Recknor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lewiecki, E. Michael, E. J. Czerwiński, Chris Recknor, et al.. (2023). Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study. Journal of Bone and Mineral Research. 38(10). 1404–1414. 10 indexed citations

Dussen, Daniel J. Van, et al.. (2021). Hospitalization in High Fracture Risk Older Adults with Osteoporosis Using the Safe Functional Motion Test: A Longitudinal Analysis. Gerontology and Geriatric Medicine. 7. 3697076617–3697076617. 2 indexed citations

Hofbauer, Lorenz C., Zsuzsanna Varga, László B. Tankó, et al.. (2021). Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial. The Lancet Healthy Longevity. 2(5). e263–e274. 26 indexed citations

Czerwiński, E. J., José Cardona, Chris Recknor, et al.. (2020). The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial. Journal of Bone and Mineral Research. 37(12). 2435–2442. 23 indexed citations

Berry, Sarah D., Alyssa B. Dufour, Thomas G. Travison, et al.. (2018). Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting. Archives of Osteoporosis. 13(1). 124–124. 8 indexed citations

Adachi, Jonathan D., Henry G. Bone, Nadia Daizadeh, et al.. (2017). Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC Musculoskeletal Disorders. 18(1). 174–174. 11 indexed citations

Genant, Harry K., Klaus Engelke, Michael A. Bolognese, et al.. (2016). Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass. Journal of Bone and Mineral Research. 32(1). 181–187. 100 indexed citations

Dent, Ricardo, C. Stephen Djedjos, Jason C. Legg, et al.. (2016). Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. SpringerPlus. 5(1). 300–300. 20 indexed citations

Whitmarsh, Tristan, Graham M. Treece, AH Gee, et al.. (2014). Romosozumab and Teriparatide Effects on Vertebral Cortical Mass, Thickness, and Density in Postmenopausal Women With Low Bone Mineral Density (BMD).. Cambridge University Engineering Department Publications Database. 5 indexed citations

10.

Recknor, Chris, E. J. Czerwiński, Henry G. Bone, et al.. (2013). Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy. Obstetrics and Gynecology. 121(6). 1291–1299. 110 indexed citations

11.

McClung, Michael R., José Zanchetta, Arne Høiseth, et al.. (2012). Denosumab Densitometric Changes Assessed by Quantitative Computed Tomography at the Spine and Hip in Postmenopausal Women With Osteoporosis. Journal of Clinical Densitometry. 16(2). 250–256. 26 indexed citations

12.

Sambrook, Philip N., Stuart L. Silverman, Jane A. Cauley, et al.. (2011). Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT. Bone. 48(6). 1298–1304. 15 indexed citations

13.

Adachi, Jonathan D., Kenneth W. Lyles, Cathleen Colón‐Emeric, et al.. (2011). Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial. Osteoporosis International. 22(9). 2539–2549. 25 indexed citations

14.

Wark, John D., W. Bensen, Chris Recknor, et al.. (2011). Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporosis International. 23(2). 503–512. 55 indexed citations

15.

Adachi, Jonathan D., Kenneth W. Lyles, Steven Boonen, et al.. (2011). Subtrochanteric Fractures in Bisphosphonate-Naive Patients: Results from the HORIZON-Recurrent Fracture Trial. Calcified Tissue International. 89(6). 427–433. 10 indexed citations

16.

Recknor, Chris. (2011). Zoledronic acid for prevention and treatment of osteoporosis. Expert Opinion on Pharmacotherapy. 12(5). 807–815. 15 indexed citations

17.

Colón‐Emeric, Cathleen, Lars Nordsletten, Nancy M. Major, et al.. (2010). Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporosis International. 22(8). 2329–2336. 69 indexed citations

18.

Eriksen, Erik Fink, Kenneth W. Lyles, Cathleen Colón‐Emeric, et al.. (2009). Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture. Journal of Bone and Mineral Research. 24(7). 1308–1313. 100 indexed citations

19.

McClung, Michael R., Paul D. Miller, Chris Recknor, et al.. (2009). Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics and Gynecology. 114(5). 999–1007. 84 indexed citations

20.

Lyles, Kenneth W., Cathleen Colón‐Emeric, Jay Magaziner, et al.. (2007). Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. New England Journal of Medicine. 357(18). 1799–1809. 1401 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact